RxDoctor Payments Data

Brittney Fisher

Acute Care · Temple, TXNPI 1568193118

Payments from drug & device makers

$658in general payments, 2019–2025

Across 20 payments — averaging $32.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$187
  • AstraZeneca$150
  • Amgen$145
  • Veloxis Pharmaceuticals, Inc.$92
  • Mallinckrodt Hospital Products Inc.$33
  • OPKO Pharmaceuticals, LLC$31
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$56686%
  • Education$9214%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$658 in reported general payments places this provider in the 60th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$30,256
Medicare patients
233
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin12$16,833
VeltassaPatiromer Calcium Sorbitex11$16,755
FarxigaDapagliflozin Propanediol16$12,968
Losartan Potassium51$689
Tamsulosin Hcl16$507
Lisinopril30$404
Calcitriol16$396
Torsemide16$372
Amlodipine Besylate42$338
Carvedilol14$333
Spironolactone18$287
Potassium Chloride16$219
Furosemide20$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$20$16,83312 claims
AstraZenecaFarxiga$150$12,96816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,323 acute care providers in Texas.

Other acute care in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →